Document is current
Any future updates will be listed below
-
Authors
Birlea, Marius https://orcid.org/0000-0002-4663-2084
Robinson, Christopher L. https://orcid.org/0000-0002-6276-9056
Mama, Eden https://orcid.org/0009-0000-5076-7427
Stark-Inbar, Alit https://orcid.org/0000-0001-6434-6447
Ironi, Alon https://orcid.org/0000-0002-3992-4978
Atashsokhan, Daniel https://orcid.org/0009-0005-9747-7773
Berk, Thomas https://orcid.org/0000-0002-8383-8444
-
Funding
Funding for this research was provided by:
Theranica
- License Information
-
More Information
Article History
Received: 10 September 2025
Accepted: 5 November 2025
First Online: 27 November 2025
Declarations
:
: All reported studies/experiments with human or animal subjects performed by the authors have been previously published and complied with all applicable ethical standards (including the Helsinki declaration and its amendments, institutional/national research committee standards, and international/national/institutional guidelines).
: Marius Birlea participated in an Advisory Board for Abbvie. Thomas Berk is an employee of Neura Health and Amneal Pharmaceuticals. Alit Stark-Inbar and Eden Mama are Theranica employes. Alon Ironi is Theranica Employee and stockholder. Christopher Robinson is a Section Editor of this journal in “Alternative Treatments for Pain Medicine” collection and has no relevant financial or non-financial interests to disclose. Daniel Atashsokhan has no relevant financial or non-financial interests to disclose.
